![Jim Banting](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Jim Banting
Algemeen Directeur bij
PARTEQ Innovations
Profiel
Dr. Jim Banting is President & Chief Executive Officer at PARTEQ Innovations.
Prior to joining PARTEQ Innovations, Dr. Banting was employed as Head of Business Development by Sigma-Tau Pharmaceuticals, Inc., a U.S.
company focused on rare diseases.
Previously, he spent six years in the business development group of the U.S.
biotechnology company Human Genome Sciences.
In that role, he led the due diligence and negotiation of a number of in- and out-licensing, manufacturing, platform, and co-development related collaborations.
He has also worked at the proteomics company Caprion, securing numerous biomarker discovery collaborations with industry partners.
His career began as a co-founder of the Queen's spin-off company Vaxis Therapeutics that was funded by venture capitalists.
After growing the company, Dr. Banting served as the business development lead on the sale of Vaxis to a U.S.
specialty pharmaceutical company.
Dr. Banting graduated from Queen's in 1993 with an honours degree in Life Sciences.
He earned his doctorate in pharmacology at Queen's.
Actieve functies van Jim Banting
| Bedrijven | Functie | Begin |
|---|---|---|
PARTEQ Innovations
 PARTEQ Innovations Investment ManagersFinance PARTEQ Innovations makes equity and debt investments to commercialize technologies developed in their life and physical sciences programs. It provides financing for early stage capital requirement with an investments range from $50,000 to $150,000. | Algemeen Directeur | - |
Eerdere bekende functies van Jim Banting
| Bedrijven | Functie | Einde |
|---|---|---|
Vaxis Therapeutics Corp
 Vaxis Therapeutics Corp Pharmaceuticals: MajorHealth Technology Manufactures and also researches pharmaceutical products | Corporate Officer/Principal | - |
Leadiant Biosciences, Inc.
 Leadiant Biosciences, Inc. Pharmaceuticals: MajorHealth Technology Develops novel medicines for rare diseases | Corporate Officer/Principal | - |
Human Genome Sciences, Inc.
 Human Genome Sciences, Inc. Medical SpecialtiesHealth Technology Provides pharmaceutical and diagnostic products | Corporate Officer/Principal | - |
Opleiding van Jim Banting
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
100
+
Eerstegraads connecties
5
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
| Bedrijven in privébezit | 5 |
|---|---|
Human Genome Sciences, Inc.
Human Genome Sciences, Inc. Medical SpecialtiesHealth Technology Provides pharmaceutical and diagnostic products | Health Technology |
Vaxis Therapeutics Corp
Vaxis Therapeutics Corp Pharmaceuticals: MajorHealth Technology Manufactures and also researches pharmaceutical products | Health Technology |
Queen's University
 Queen's University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Leadiant Biosciences, Inc.
Leadiant Biosciences, Inc. Pharmaceuticals: MajorHealth Technology Develops novel medicines for rare diseases | Health Technology |
PARTEQ Innovations
PARTEQ Innovations Investment ManagersFinance PARTEQ Innovations makes equity and debt investments to commercialize technologies developed in their life and physical sciences programs. It provides financing for early stage capital requirement with an investments range from $50,000 to $150,000. | Finance |
